Evidence map›Paper›PMID 39070148›Full record

ArticleFrontiers in oncology2024

Increased risk of cardiovascular disease among kidney cancer survivors: a nationwide population-based cohort study.

Minji Jung, Eunjung Choo, Shufeng Li, Zhengyi Deng, Jinhui Li, Mingyi Li, Satvir Basran, Sukhyang Lee, Marvin E Langston, Benjamin I Chung

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Minji JungDepartment of Urology, Stanford University Medical Center, Stanford, CA, United States.
Eunjung ChooDepartment of Clinical Pharmacy, School of Pharmacy, Ajou University, Suwon, Republic of Korea.
Shufeng LiDepartment of Urology, Stanford University Medical Center, Stanford, CA, United States.
Zhengyi DengDepartment of Urology, Stanford University Medical Center, Stanford, CA, United States.
Jinhui LiDepartment of Urology, Stanford University Medical Center, Stanford, CA, United States.
Mingyi LiDepartment of Urology, Stanford University Medical Center, Stanford, CA, United States.
Satvir BasranDepartment of Urology, Stanford University Medical Center, Stanford, CA, United States.
Sukhyang LeeDepartment of Clinical Pharmacy, School of Pharmacy, Ajou University, Suwon, Republic of Korea.
Marvin E Langston *Department of Urology, Stanford University Medical Center, Stanford, CA, United States.
Benjamin I Chung *Department of Urology, Stanford University Medical Center, Stanford, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiovascular disease (CVD) is a major concern of morbidity and mortality among cancer survivors. However, few evidence exists on the short- and long-term risk of CVD in kidney cancer (KCa) survivors. Methods: In this nationwide, large population-based retrospective cohort study, we used the Korean national health insurance and medical checkup survey linkage database (2007-2021), drawn from the entire Korean population. We included adults diagnosed with KCa as the first primary cancer and matched them to an individual without KCa at a 1:5 ratio. The primary outcome was CVD incidence, including myocardial infarction, stroke, atrial fibrillation, heart failure, peripheral arterial occlusion, and venous thromboembolism (VTE). We evaluated CVD risk at 6 months, 1 year, and 5 years following cancer diagnosis, using Fine-Gray competing risk models that accounted for death as a competing factor. Results: A total of 149,232 participants were included (KCa survivors: N=20,093 and matched non-KCa individuals: N=129,139). After 6-month follow-up, KCa survivors showed an increased risk of CVD compared to the general population (subdistribution hazard ratio (HR) 2.70, 95% confidence interval (CI) 2.31-3.15). After 1 year, KCa survivors had a higher risk of CVD (HR=1.77, 95% CI: 1.56-2.00). After 5 years, this elevated CVD risk remained (HR=1.10, 95% CI: 1.03-1.18), with VTE identified as the primary contributing disease (HR=3.05, 95% CI:2.59-3.59). Conclusion: KCa survivors had an increased risk of CVD up to 5 years after cancer diagnosis compared to the general population. Our findings emphasize the importance of comprehensive healthcare management for both CVD and KCa throughout cancer survivorship.

Indexed as

cancer survivorshipcardiooncologycardiovascular diseasekidney cancerprimary prevention

Identifiers

PMID39070148
PMCPMC11272517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.